Evaluating the Role of Novel Oncology Agents: Oncology Stewardship in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
| Autor: | Victoria R Nachar, Bernard L. Marini, Tycel Phillips, Lydia L. Benitez, Brian Bazzell, Anthony J. Perissinotti |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Adolescent Salvage treatment Young Adult 03 medical and health sciences 0302 clinical medicine Refractory Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Aged Aged 80 and over business.industry Treatment options Hematology Middle Aged medicine.disease Lymphoma Novel agents 030220 oncology & carcinogenesis Relapsed refractory Female Lymphoma Large B-Cell Diffuse Stewardship business Diffuse large B-cell lymphoma 030215 immunology |
| Zdroj: | Clinical Lymphoma Myeloma and Leukemia. 21:295-308 |
| ISSN: | 2152-2650 |
| DOI: | 10.1016/j.clml.2020.12.018 |
| Popis: | Novel treatment strategies have shifted the treatment landscape for patients with diffuse large B-cell lymphoma, particularly for those with relapsed/refractory disease. However, uncertainty remains regarding the therapeutic value of these novel agents compared to existing salvage chemotherapy regimens. In addition, the high cost associated with these agents puts both patients and health systems at risk of financial toxicity, further complicating their use. The development of clinical pathways incorporating oncology stewardship principles are necessary in order to maximize value-based care. This comprehensive review assesses the efficacy and safety data available for novel treatment options in relapsed/refractory diffuse large B-cell lymphoma and applies stewardship principles to evaluate their optimal place in therapy, with the aim of optimizing safe, effective, and financially responsible patient care. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect